logo-loader

PreveCeutical Medical Inc outlines recent health care milestones

Last updated: 23:56 24 Aug 2018 AEST, First published: 18:56 24 Aug 2018 AEST

1535119127_Scientist-looking-through-microscope
PreveCeutical describes itself as a health sciences group

PreveCeutical Medical Inc (CNSX:PREV), the health sciences group with a focus on natural products, outlined its several recent milestones  as it updated on operations.  

One was a deal this month with Asterion Cannabis Inc, which gives it  the licence to use, manufacture, distribute and sell three Health Canada-approved natural health products, it said.

Preveceutical has also launched a medicinal cannabis division; completed a C$6.5mln financing, and expanded its Australian operations.

There, it has reached all its research targets in its scorpion-venom-derived peptide program and the soluble gel (sol-gel) drug delivery platform program.

The proceeds of the financing will be used to finance the company's research and development (R&D) programs and for general working capital purposes.

The medicinal cannabis division will focus on bringing medicinal cannabis-based products developed by the company to market and overseeing the company's sol-gel program and its resultant formulations.

Through the sale of the medical cannabis products, the firm aims to help consumers address a number of ailments, including chronic pain, epilepsy, anxiety disorders and more.

Shares in PreveCeutical Medical stand at C$0.04 today (Friday).

PreveCeutical prepares for the final stage of their Sol-Gel program

PreveCeutical (CNSX:PREV) Chief Research Officer Dr Harry Parekh joined Steve Darling from Proactive Investors Vancouver to talk about the companies progress in the development of their sol-gel. Parekh telling proactive the next step they are undertaking with human tissue. He also talked...

on 27/4/19